Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MonoSol Rx, a drug delivery company specializing in quick dissolving thin film pharmaceutical products, has received a new US patent from the US Patent and Trademark Office.
Subscribe to our email newsletter
The patent, which is expected to issue on September 16, 2008, relates to the company’s proprietary processes for manufacturing a broad range of prescription and over-the-counter products with controlled uniformity of drug content.
The patent provides broad protection for the company’s drug-containing film manufacturing process and represents the first film patent of its kind to protect the manufacturing process and its ability to insure consistent dosing of medication in each strip.
The patented process also includes steps to preserve the stability of drugs and other active ingredients, by a procedure which permits inclusion of the most sensitive actives in a way which protects them from interacting or losing their potency when the dosage form is manufactured.
Mark Schobel, president and CEO of MonoSol Rx, said: “The granting of this patent further validates MonoSol Rx and our PharmFilm technology as leaders and innovators in the field of thin film drug delivery technology.
“This patent represents a significant border of protection for MonoSol Rx around the manufacture of its pharmaceutical thin films and will present new challenges for competing companies to achieve uniformity of drug content in a safe, efficient, and cost effective manner.”